209 related articles for article (PubMed ID: 7670926)
1. Presymptomatic genetic screening in families with multiple endocrine neoplasia type 2.
Frilling A; Höppner W; Eng C; Mulligan L; Raue F; Broelsch CE
J Mol Med (Berl); 1995 May; 73(5):229-33. PubMed ID: 7670926
[TBL] [Abstract][Full Text] [Related]
2. Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.
Frilling A; Dralle H; Eng C; Raue F; Broelsch CE
Surgery; 1995 Dec; 118(6):1099-103; discussion 1103-4. PubMed ID: 7491529
[TBL] [Abstract][Full Text] [Related]
3. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.
Sanso GE; Domene HM; Garcia R; Pusiol E; de M; Roque M; Ring A; Perinetti H; Elsner B; Iorcansky S; Barontini M
Cancer; 2002 Jan; 94(2):323-30. PubMed ID: 11900218
[TBL] [Abstract][Full Text] [Related]
4. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].
Sansó G; Domené HM; Iorcansky S; Barontini M
Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.
Kambouris M; Jackson CE; Feldman GL
Hum Mutat; 1996; 8(1):64-70. PubMed ID: 8807338
[TBL] [Abstract][Full Text] [Related]
6. [Prophylactic total thyroidectomy in children and adolescents with genetic mutations in the RET-protooncogene].
Spinelli C; Puccini M; Bertocchini A; Lima M; Pacini F; Miccoli P
Pediatr Med Chir; 2002; 24(1):53-7. PubMed ID: 11938683
[TBL] [Abstract][Full Text] [Related]
7. Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A.
Vieira AE; Mello MP; Elias LL; Lau IF; Maciel LM; Moreira AC; Castro M
Horm Metab Res; 2002 Apr; 34(4):202-6. PubMed ID: 11987030
[TBL] [Abstract][Full Text] [Related]
8. [Management of multiple endocrine neoplasia syndrome type 2 families in association with rare germline mutations of the RET proto-oncogene].
Fitze G; Saeger HD; Roesner D; Schackert HK
Klin Padiatr; 2004; 216(5):270-6. PubMed ID: 15455293
[TBL] [Abstract][Full Text] [Related]
9. Treatment of minute medullary thyroid carcinoma in multiple endocrine neoplasia 2A families first diagnosed by DNA analysis of RET proto-oncogene mutations: a case report.
Yamashita T; Lihara M; Okamoto J; Kanbe M; Ito Y; Kawakami M; Egawa S; Yamaguchi K; Obara T
Jpn J Clin Oncol; 1997 Feb; 27(1):42-5. PubMed ID: 9070340
[TBL] [Abstract][Full Text] [Related]
10. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
[TBL] [Abstract][Full Text] [Related]
11. [Preventive radical surgery of C-cell carcinoma in MEN-II syndrome based on genetic screening].
Röher HD; Simon D; Goretzki PE; Höppner W; Lederbogen S; Seppel T
Chirurg; 1995 Dec; 66(12):1196-202. PubMed ID: 8582162
[TBL] [Abstract][Full Text] [Related]
12. Molecular genetic diagnostic program of multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma syndromes in Hungary.
Klein I; Esik O; Homolya V; Szeri F; Váradi A
J Endocrinol; 2001 Sep; 170(3):661-6. PubMed ID: 11524247
[TBL] [Abstract][Full Text] [Related]
13. [Prophylactic thyroidectomy in children who are carriers of a multiple endocrine neoplasia type 2 mutation: description of 20 cases and recommendations based on the literature].
de Groot JW; Links TP; Rouwe CW; van der Wal JE; Hofstra RM; Plukker JT
Ned Tijdschr Geneeskd; 2006 Feb; 150(6):311-8. PubMed ID: 16503023
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic thyroidectomy for MEN 2-related medullary thyroid carcinoma based on predictive testing for RET proto-oncogene mutation and basal serum calcitonin in China.
Qi XP; Zhao JQ; Du ZF; Yang RR; Ma JM; Fei J; Cheng J; Han JS; Jin HY; Chen ZG; Wang JQ; Yang YP; Ying RB; Chen XL; Liu WT; Zhao Y; Jiang HL; Zhang XN
Eur J Surg Oncol; 2013 Sep; 39(9):1007-12. PubMed ID: 23849459
[TBL] [Abstract][Full Text] [Related]
15. Multiple endocrine neoplasia type 2A with the identical somatic mutation in medullary thyroid carcinoma and pheochromocytoma without germline mutation at the corresponding site in the RET proto-oncogene.
Akama H; Noshiro T; Kimura N; Shimizu K; Watanabe T; Shibukawa S; Nakai S; Miura W; Ito S; Miura Y
Intern Med; 1999 Feb; 38(2):145-9. PubMed ID: 10225670
[TBL] [Abstract][Full Text] [Related]
16. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
17. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s.
Zedenius J; Wallin G; Hamberger B; Nordenskjöld M; Weber G; Larsson C
Hum Mol Genet; 1994 Aug; 3(8):1259-62. PubMed ID: 7987299
[TBL] [Abstract][Full Text] [Related]
18. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)".
Fink M; Weinhüsel A; Niederle B; Haas OA
Int J Cancer; 1996 Aug; 69(4):312-6. PubMed ID: 8797874
[TBL] [Abstract][Full Text] [Related]
19. A nationwide clinical survey of patients with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma in Japan.
Iihara M; Yamashita T; Okamoto T; Kanbe M; Yamazaki K; Egawa S; Yamaguchi K; Obara T
Jpn J Clin Oncol; 1997 Jun; 27(3):128-34. PubMed ID: 9255265
[TBL] [Abstract][Full Text] [Related]
20. Lessons learned from the management of a rare genetic cancer.
Cote GJ; Gagel RF
N Engl J Med; 2003 Oct; 349(16):1566-8. PubMed ID: 14561800
[No Abstract] [Full Text] [Related]
[Next] [New Search]
